Given that NSD2 is known to play a relevant role in multiple myeloma relapse and treatment resistance [94,98], genetic and epigenetic compounds should be found capable of inhibiting NSD2 activity regardless of the nature of its alteration. The gene discussed is NSD2; the disease is AL amyloidosis.